No biomarker	Germ Cell Tumors	No biomarker	Germ Cell Tumors	dactinomycin Sensitive: A1 - Approval dactinomycin Sensitive : A1	dactinomycin Sensitive: A1 - Approval dactinomycin Sensitive : A1
No biomarker	Ewing Sarcoma	No biomarker	Ewing Sarcoma	dactinomycin Sensitive: A1 - Approval dactinomycin Sensitive : A1	dactinomycin Sensitive: A1 - Approval dactinomycin Sensitive : A1
No biomarker	Rhabdomyosarcoma	No biomarker	Rhabdomyosarcoma	dactinomycin Sensitive: A1 - Approval dactinomycin Sensitive : A1	dactinomycin Sensitive: A1 - Approval dactinomycin Sensitive : A1
No biomarker	Rhabdomyosarcoma	No biomarker	Rhabdomyosarcoma	vincristine + dactinomycin Sensitive: A2 - Guideline vincristine + dactinomycin Sensitive : A2	vincristine + dactinomycin Sensitive: A2 - Guideline vincristine + dactinomycin Sensitive : A2
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	dactinomycin Sensitive: C2 – Inclusion Criteria dactinomycin Sensitive : C2	dactinomycin Sensitive: C2 – Inclusion Criteria dactinomycin Sensitive : C2
ETV6-NTRK3 fusion	Fibrosarcoma	ETV6-NTRK3 fusion	Fibrosarcoma	vincristine + dactinomycin Resistant: C4 – Case Studies vincristine + dactinomycin Resistant : C4	vincristine + dactinomycin Resistant: C4 – Case Studies vincristine + dactinomycin Resistant : C4
TOP2A overexpression	Adrenal Cortex Carcinoma	TOP2A overexpression	Adrenal Cortex Carcinoma	pirarubicin Sensitive: D – Preclinical pirarubicin Sensitive : D	pirarubicin Sensitive: D – Preclinical pirarubicin Sensitive : D
IDH2 mutation	Glioma	IDH2 mutation	Glioma	dactinomycin Sensitive: D – Preclinical dactinomycin Sensitive : D	dactinomycin Sensitive: D – Preclinical dactinomycin Sensitive : D
IDH1 mutation	Glioma	IDH1 mutation	Glioma	dactinomycin Sensitive: D – Preclinical dactinomycin Sensitive : D	dactinomycin Sensitive: D – Preclinical dactinomycin Sensitive : D

RNA synthesis inhibitor

RNA synthesis inhibitor

Associations(9)

Associations
(9)